Latest News and Press Releases

REDWOOD CITY, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy...

First Patient Dosed in Phase 1 trial of Briquilimab in Lower-Risk Myelodysplastic SyndromeStrengthened the Board of Directors and Management Team with Multiple Appointments REDWOOD CITY, Calif., Aug....

Announced Planned Development Expansion of Briquilimab in Chronic Spontaneous UrticariaPresented Positive Follow-up Clinical Data from Investigator-Sponsored Study of Briquilimab Conditioning in...

Positive Clinical Data Presented at IEWP Annual Meeting from Investigator Sponsored Study of JSP191 Conditioning Showed 100% Donor Chimerism in First Two Fanconi Anemia PatientsFast Track Designation...

Successful meeting with the FDA; the Company intends to initiate registrational studies in MDS and AML in Q1-2023Clinical data from the Phase 1 study of JSP191 as a conditioning regimen in patients...

REDWOOD CITY, Calif., March 18, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on transforming the field of hematopoietic stem cell therapies,...

REDWOOD CITY, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced that...

REDWOOD CITY, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced the...

JSP191 is well tolerated with no treatment-related severe adverse events in 17 subjects with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) in Ph1b dose expansion study17 of 17...

JSP191 is well tolerated with no treatment-related adverse events in dose-escalation studySingle-agent conditioning with JSP191 is associated with engraftment, immune reconstitution, and clinical...